tbuckley/cabot-search huggingface dataset:
Abstract 14853: Acute Inhibition of Mitochondrial Reactive Oxidative Species Improves Endothelial SK Channel Function Following Cardioplegic Hypoxia/Reperfusion and Diabetes
Authors: Yi Song, Zhiqi Zhang, Hang Xing, Yixin He, guangbin shi, Su Wu, Elizabeth O Harrington, Frank W Sellke, Jun Feng
Journal: Circulation (2020)

Introduction: Cardioplegic-ischemia/reperfusion (CP-I/R) and diabetes mellitus (DM) are correlated with coronary endothelial dysfunction and inactivated small conductance calcium-activated-potassium (SK) channels. Increased reactive oxidative species (ROS), such as mitochondrial ROS (mROS) may contribute to oxidative injury. Thus, we hypothesized that inhibition of mROS may protect coronary SK channels and endothelial function against CP-I/R-induced injury. Objective: A cardioplegic hypoxia and reoxygenation (CP-H/R) model consisting of coronary endothelial cells and small coronary arteries with or without DM were employed for examining whether MT could protect against coronary endothelial and SK channel dysfunction. Methods: Small coronary arteries (&lt;150μm) and endothelial cells (MHECs) were dissected from the mouse heart with non-diabetes (ND) and DM (n=6/group). The microvessels or MHECs were subjected to hypoxia with cardioplegia and re-oxygenated. The microvessels or MHECs were treated with or without MT (10 -5 M) 5-minutes before and during CP-hypoxia. Microvascular vasodilation function was assessed in vitro by administration of vasoconstrictor, then ADP or NS309,respectively. K + currents of MHECs were measured by whole-cell patch clamp. The levels of endothelial mROS was measured by MitoSox TM . Results: CP-H/R significantly attenuated endothelial SK channels activity and the coronary relaxation responses to ADP and NS309 in the ND and DM groups. Treatment with MT enhanced coronary relaxation responses to ADP or NS309 ( p &lt;0.05, Fig 1. A, B), and similar findings were seen in endothelial SK channel currents in both ND and DM MHECs ( p &lt;0.05, Fig 1. C-F). In addition, treating MHECs with MT reduced CP-H/R-induced mROS in ND and DM groups. Conclusions: Administration of MT improves endothelial SK channels activity which may contribute to its enhancement of endothelium-dependent vasorelaxation following CP-H/R.
Signals of pseudo-starvation unveil the amino acid transporter SLC7A11 as key determinant in the control of Treg cell proliferative potential
Authors: Claudio Procaccini, Silvia Garavelli, Fortunata Carbone, Dario Di Silvestre, Claudia La Rocca, Dario Greco, Alessandra Colamatteo, Maria Teresa Lepore, Claudia Russo, Giusy De Rosa, Deriggio Faicchia, Francesco Prattichizzo, Sarah Grossi, Paola Campomenosi, Fabio Buttari, Pierluigi Mauri, Antonio Uccelli, Marco Salvetti, Vincenzo Brescia Morra, Danila Vella, Mario Galgani, Maria Mottola, Bruno Zuccarelli, Roberta Lanzillo, Giorgia Teresa Maniscalco, Diego Centonze, Paola de Candia, Giuseppe Matarese
Journal: Immunity (2021)
Safety and efficacy of rituximab in patients with diffuse large B-cell lymphoma in Malawi: a prospective, single-arm, non-randomised phase 1/2 clinical trial
Authors: Stephen Kimani, Matthew S Painschab, Bongani Kaimila, Edwards Kasonkanji, Takondwa Zuze, Tamiwe Tomoka, Maurice Mulenga, Richard Nyasosela, Maria Chikasema, Asekanadziwa Mtangwanika, Mena Chawinga, Wilberforce Mhango, Simon Nicholas, Fred Chimzimu, Coxcilly Kampani, Robert Krysiak, Amy Lilly, Cara Randall, Ryan Seguin, Katherine D Westmoreland, Nathan D Montgomery, Yuri Fedoriw, Satish Gopal
Journal: The Lancet Global Health (2021)

There are no clinical trials involving patients with diffuse large B-cell lymphoma (DLBCL) in sub-Saharan Africa since antiretroviral therapy (ART) for HIV became widely available in this region. We aimed to establish the safety and efficacy of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with DLBCL in Malawi.
TREATMENT OF CHRONIC NON-A, NON-B HEPATITIS WITH IFN-ALPHA-2B
Authors: Iino S, Yasuda K, Koike K, Kurai K, Kurokawa K, Hino K, Kondo T, Fujioka S, Kaku K, Kanno T, Shimoda K, Niwa H
Journal: Hepatology (1990)
Abstract 073: Physical Function And Subsequent Risk Of Cardiovascular Events In Older Adults: The Atherosclerosis Risk In Communities (ARIC) Study
Authors: Xiao Hu, Yejin Mok, Ning Ding, Kevin Sullivan, Pamela L Lutsey, Jennifer Schrack, Priya Palta, Kunihiro Matsushita
Journal: Circulation (2021)

Background: Reduced physical function, an exemplary phenotype of aging, has been associated with cardiovascular disease (CVD). However, few studies have comprehensively investigated the association of physical function with risk of incident and recurrent CVD in community-dwelling older adults. Methods: Physical function, evaluated with the Short Performance Physical Battery (SPPB), was assessed in the ARIC study at visit 5 (2011-2013) among 5548 participants (mean age 75±5 years, female 58%, black 22%). The SPPB score was categorized into low (0-6), intermediate (7-9), and high (10-12) physical function. We assessed the associations of SPPB categories with composite and individual outcomes of coronary heart disease (CHD), stroke, or heart failure (HF) using Cox proportional hazards models adjusting for potential confounders. We also evaluated improvement in c-statistics by adding SPPB to covariates. Results: During a median follow-up of 6.2 years, there were 821 composite events (329 CHD, 226 stroke, and 467 HF cases). Compared to high SPPB score, low and intermediate SPPB score were robustly associated with higher risk of the composite CVD outcome (hazard ratio [HR] 1.59 [95% CI 1.29-1.95] and 1.32 [1.12-1.56], respectively) (Table). These associations were largely consistent between participants with and without a history of CVD at baseline. Among individual outcomes, low SPPB score showed the highest HR for stroke, whereas intermediate SPPB score was only significantly associated with HF. The addition of SPPB significantly improved c-statistic for composite outcome (Δc-statistic 0.006 [95% CI 0.002-0.009]), and the improvement was especially evident in participants without history of CVD (Δc-statistic 0.013 [0.003-0.023]). Conclusions: Lower physical function was robustly associated with the risk of CVD and improved its prediction beyond established predictors in older adults. Clinicians should pay attention to physical function when managing CVD risk in older adults.
Abstract 12691: Long-term Optimal Medical Therapy for Patients With Mid-range Left Ventricular Ejection Fraction After Acute Myocardial Infarction
Authors: YeeKyoung KO, Seungjae JOO, Jong Wook Beom, Jae-Geun Lee, Joon-Hyouk CHOI, Song-Yi KIM, Myung Ho JEONG
Journal: Circulation (2020)

Introduction: In the era of the initial optimal interventional and medical therapy for acute myocardial infarction (AMI), a number of patients with mid-range left ventricular ejection fraction (40% &lt;EF&lt;50%) becomes increasing. However, the long-term optimal medical therapy for these patients has been rarely studied. Aims: This observational study aimed to investigate the association between the medical therapy with beta-blockers or inhibitors of renin-angiotensin system (RAS) and clinical outcomes in patients with mid-range EF after AMI. Methods: Among 13,624 patients enrolled in the Korea Acute Myocardial Infarction Registry-National Institute of Health (KAMIR-NIH), propensity-score matched patients who survived the initial attack and had mid-range EF were selected according to beta-blocker or RAS inhibitor therapy at discharge. Results: Patients with beta-blockers showed significantly lower 1-year cardiac death (2.4 vs. 5.2/100 patient-year; hazard ratio [HR] 0.46; 95% confidence interval [CI] 0.22-0.98; P =0.045) and MI (1.7 vs. 4.0/100 patient-year; HR 0.41; 95% CI 0.18-0.95; P =0.037). On the other hand, RAS inhibitors were associated with lower 1-year re-hospitalization due to heart failure (2.8 vs. 5.5/100 patient-year; HR 0.54; 95% CI 0.31-0.92; P =0.024), and no significant interaction with classes of RAS inhibitors (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) was observed ( P for interaction=0.332). Conclusions: Beta-blockers or RAS inhibitors at discharge were associated with better 1-year clinical outcomes in patients with mid-range EF after AMI.
28P EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy
Authors: J. Leichsenring, V. Vladimirova, C. Solbach, T. Karn, B. Ataseven, B. Sinn, J. Barinoff, V. Mueller, J-U. Blohmer, C. Schem, K. Engels, F. Marmé, A. Fissler-Eckhoff, P.A. Fasching, E. Stickeler, M. van Mackelenbergh, C. Denkert, A. Stenzinger, S. Loibl, S. Gröschel
Journal: Annals of Oncology (2021)
Coordinate posttranscriptional regulation of cancer genes by the RNA binding protein HuR
Authors: Ulus Atasoy, Joseph Magee, Matt Gubin
Journal: Cancer Research (2008)

176  Due to the poor correlation between steady state mRNA levels and protein products, traditional microarray analysis may miss many genes which are regulated primarily at the level of mRNA stability and translation. Posttranscriptional gene regulation is becoming increasingly recognized as an important form of cellular control. Whereas our understanding of transcriptional regulation is advanced, in contrast this area remains largely unexplored. Yet, increasingly, the importance of microRNAs and RNA binding proteins (RBPs) is now beginning to be better appreciated. We study the elav (embryonic lethal abnormal vision) family of RBPs, which are paraneoplastic antigens, over-expressed in a variety of malignancies, including breast cancer. Antibodies against elav family members are believed to be cancer-protective. The elav family of RBPs binds to the AU-rich elements (AREs) found in the 3’ untranslated regions (UTRs) of many early-response genes, including proto-oncogenes and cell cycle regulators. HuR, the ubiquitously expressed family member, has recently been described to play a role in cancer progression. HuR stabilizes and translationally up regulates the expression of its target mRNAs. Elevated levels of cytoplasmic HuR directly correlate with increased invasiveness of malignancy and poor prognosis for many cancers, including those of the breast. HuR has been described to control the expression of genes in all six different areas of transformation originally described by Hanahan and Weinberg. Hence, it has been recently suggested that HuR may serve as a tumor maintenance gene which allows for cancers, once they are established, to proliferate. Therefore, it is of interest to discover in vivo HuR targets, as these genes may play vital roles in transformed cells. We have developed methods which enable us to identify en masse, in vivo targets of RBPs such as HuR from cell lines and now for the first time, solid tissues as well. We call this ribonomic analysis, in which we immunoprecipitate subsets of ribonuclear particles (RNPs), exact the mRNA and then apply to microarrays. This technique, in which no cross linking is used, allows one to en masse identify different in vivo mRNA targets which different RBPs interact with. Using a combination of HuR immunoprecipitation and RNA interference, we have been able to identify HuR in vivo targets which may play important roles in tumor maintenance. Furthermore, we present evidence of cross talk amongst stabilizer and de-stabilizer RBPs which can potentially regulate the expression of multiple cancer targets. These techniques have the potential to better delineate genes whose steady state mRNA levels may not significantly change, but which are translationally active inside cancer cells. Potentially the identification of such genes may offer novel therapeutic targets to inhibit cancer growth.
Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancer
Authors: Deli Liu, Michael A. Augello, Ivana Grbesa, Davide Prandi, Yang Liu, Jonathan E. Shoag, R. Jeffrey Karnes, Bruce J. Trock, Eric A. Klein, Robert B. Den, Francesca Demichelis, Elai Davicioni, Andrea Sboner, Christopher E. Barbieri
Journal: Journal of Clinical Investigation (2021)

BACKGROUND. Molecular characterization of prostate cancer (PCa) has revealed distinct subclasses based on underlying genomic alterations occurring early in the natural history of the disease. However, how these early alterations influence subsequent molecular events and the course of the disease over its long natural history remains unclear.
Abstract 047: Using Geospatial Data To Eliminate Disparities In Covid-19 Testing
Authors: Gregory W Heath, Tim Moreland, Shannon Stephenson, Jesse A Houser, Colleen Schmitt
Journal: Circulation (2021)

Introduction: The first case of COVID-19 in Chattanooga/Hamilton County, Tennessee (CHC) was identified on March 13, 2020. By early April, 51 RT-PCR confirmed cases were identified, with white, non-Hispanic males and females representing 82% (41/51) of positive cases and remaining cases representing black residents (18%; 9/51). That few people from racial/ethnic minorities were being tested became a key public health concern. We hypothesized that local mapping of health-related data would identify regions where individuals at greater risk for COVID-19 live and work and have limited access to testing and healthcare services. Methods: The CDC 500 Cities data was used to generate layered maps of prevalence estimates for cardiovascular disease, type 2 diabetes mellitus, chronic lung disease, and the behavioral risk factors of physical inactivity and obesity. Layers also included the CDC Social Vulnerability Index, age distribution, gender, race, ethnicity, and zip codes. Maps were shared with intersectoral collaborators representing the black and Hispanic/Latinx communities who provided specific neighborhood information to the maps. Collaborators included hospital systems, the local health department, community health centers, the private sector, and non-profit organizations. Maps were used to identify geographic sites for mobile and strategic testing within communities at higher risk for the spread of the coronavirus. Specific diverse neighborhoods along with worksites were then provided with testing beginning in early May and ongoing. Results: Strategic and mobile testing beginning in early May increased three-fold the number of identified new cases of COVID-19. Seventy percent (652/932) of these positive tests were among ethnically Hispanic/Latinx and 16% (149/932) among black residents. Positive tests continued to increase at a greater rate among Hispanic/Latinx and black residents compared with white residents through the months of May-July (68/10K vs. 2.6/10K, OR = 4.85, 95% CI 2.66, 9.02). Conclusions: This example of inter-sectoral collaboration, data sharing, and data use through strategic mapping of vulnerable populations for COVID-19 was an effective means to enhance COVID-19 testing and identification of positive cases throughout CHC. This expanded partnering resulting in targeted testing may be a useful approach among similar communities and subsequent outbreaks.
Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial
Authors: Assuntina G Sacco, Ruifeng Chen, Francis P Worden, Deborah J L Wong, Douglas Adkins, Paul Swiecicki, Wanxing Chai-Ho, Peter Oppelt, Debanjali Ghosh, Julie Bykowski, Alfredo Molinolo, Emily Pittman, M Valeria Estrada, Kathryn Gold, Gregory Daniels, Scott M Lippman, Amanda Natsuhara, Karen Messer, Ezra E W Cohen
Journal: The Lancet Oncology (2021)
한국인 만성 B형간염 환자에 대한 텔비부딘의 효능 및 안전성
Authors: 문영명, 황성규, Boo Sung Kim, 임규성, Cho，Mong, 김동준, 한준열, Young Seok Kim, 최호순, 안상훈
Journal: Clinical and Molecular Hepatology (2007)

배경: 텔비부딘은 L-nucleoside 유사체로 HBV에 대하여 강력한 억제 효과를 보인다. 임상시험을 통해 텔비부딘은 라비부딘에 비하여 유의하게 강력한 항바이러스 효과를 보여주었다. 이번 연구를 통해 3상 임상시험에 참여하였던 한국인 환자에 대한 텔비부딘의 효능과 안전성을 알아보고자 하였다. 방법: 다국가 3상 임상시험에 참여했던 1,367명의 만성 B형간염 환자 중 한국인 환자 101명의 52주 결과를 분석하였다. 101명의 환자들은 HBeAg 유무에 관계없이 텔비부딘 일일 600 mg 복용군 또는 라미부딘 일일 100 mg 복용군에 무작위로 배정되었다. 5 log10 copies/mL 미만으로 혈청 HBV DNA 억제가 있으면서 ALT 정상화 또는 HBeAg 양성 환자의 경우 HBeAg 소실로 정의되는 치료반응(therapeutic response)을 1차 효능 결과 변수로 정의하였다. 이차 효능 변수로 조직 반응(histologic response), HBV DNA의 감소, ALT 정상화, HBeAg 양성 환자의 경우 HBeAg의 소실을 살펴보았다. 결과: 총 101명의 환자 중 54명이 텔비부딘복용군에 배정되었고, 47명이 라미부딘 복용군에 포함되었다. 52주 투여 결과 텔비부딘 복용군에서 라미부딘에 비하여 유의하게 많은 환자들이 치료반응에 도달하였고(83% 대 62%, P=0.017), 혈청HBV DNA 감소(6.6 대 5.6 log10 copies/mL, P=0.027)와 HBV DNA의 PCR 불검출률(74% 대34%, P<0.0001)에서도 유의한 차이를 보였다. 또한 텔비부딘 복용군은 바이러스 내성(0% 대 18%, P=0.001)이 52주까지 관찰되지 않았다. 텔비부딘의 내약성은 우수하였고 라미부딘과 유사한 안전성을 보였다. 결론: 한국인 만성 B형간염 환자 중텔비부딘을 복용한 환자들이 라미부딘 복용군에 비하여 유의하게 신속하고 강력한 항바이러스 효과를 보여주었다. 텔비부딘 복용군에서 바이러스돌파현상은 관찰되지 않았고 두 약제의 안전성은 동등하였다.
Immunogenicity of Two AAV-Based COVID-19 Vaccine Candidates in Mouse Models of Aging and Obesity
Authors: D. Maciorowski, N. Zabaleta, U. Bhatt, C. Diop, W. L. Dai, R. Estelien, D. Li, A. Cucalon, A. Sheridan, R. Chauhan, L. H. Vandenberghe
Journal: Molecular Therapy (2021)
These I Wish to Keep
Authors: Reizel Polak
Journal: Annals of Internal Medicine (2021)

Ad LibitumMay 2021These I Wish to KeepReizel Polak, MSW, LICSW, MEdReizel Polak, MSW, LICSW, MEdBrookline Therapy Brookline, MassachusettsSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M20-0138 Audio Reading - “These I Wish to Keep” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads “These I Wish to Keep” by Reizel Polak, MSW, LICSW, MEd Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail with age its hazards writtenin the nondominant hand the pleasure of descending intoa vale of concentration to practice despite the samemistakes the piano with love of repetitionkeeping full attention to attend to what is saidin the midst of our conversation feeling the edge of delightover the back & forth surprises of little children speaking languageholding a thought or its sequence whole when disturbedby a trivial something staying fearless should a crueldead face be unleashed out of memoryfinding in the moment a few right words a measureof holy silence amazed alwayshow this broken vessel is held together by breath & invisible light Author, Article, and Disclosure InformationAffiliations: Brookline Therapy Brookline, MassachusettsCurrent Author Address: Reizel Polak, MSW, LICSW, MEd; e-mail, [email protected]com. PreviousarticleNextarticle Advertisement Audio Reading - “These I Wish to Keep” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads “These I Wish to Keep” by Reizel Polak, MSW, LICSW, MEd Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ FiguresReferencesRelatedDetails Metrics May 2021Volume 174, Issue 5Page: 697 ePublished: 18 May 2021 Issue Published: May 2021 Copyright & PermissionsCopyright © 2021 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Abstract 17412: Rapid Liposome Mimicking SARS-CoV-2 to Elucidate Thrombosis in Endothelialized Microfluidic Chip
Authors: Angela Lai, Sandro Satta, Susana Cavallero, Cayden Williamson, Tzung K Hsiai
Journal: Circulation (2020)

Introduction: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), poses the worst global health crisis in modern times. Thrombotic complications such as VTE, pulmonary embolism, and risk of stroke affect more than 30% of critically ill COVID-19 patients. Unfortunately, the flow dynamics and endothelial dysfunction underlying this outcome remains poorly understood. We hereby developed liposome-nanoparticles exposing functional S-Spike (Lipo-S) to simulate the cell internalization route of SARS-CoV-2. We propose to elucidate thrombosis development in a microfluidic channel lined with HAECs exposed to Lipo-S alone, or in combination with chimeric-lentiviral vectors (ch-Lenti) expressing SARS-CoV2-ORF sequences to recapitulate SARS-CoV-2 infection. Methods: Non-PEG liposomes (100 nm) with chemically attached S-Spike proteins on their surface were developed in house. Furthermore, singular regions of SARS-CoV-2-ORFs were cloned and inserted in ch-Lenti. After exposure to Lipo-S and/or ch-Lenti vectors HAECs coverage and response will be elucidated by staining of VE-Cadherin and confocal imaging. To mimic the progression of thrombosis, whole human blood containing platelets stained with CD41-PE antibody and fluorescently labeled fibrin will be flowed with an arterial shear rate of 25 dyne/cm 2 through the microfluidic chip for 15 minutes. The chip will be fixed and imaged to characterize the clot. Results: Lipo-S showed stronger interaction for ACE2 protein compared to non-coated liposomes measured by ELISA. Our previous work showed feasibility of measuring platelet and fibrin by quantifying coverage and projecting maximum intensity of the image stack for each component. Conclusion: This novel platform will uncover mechanisms underlying COVID19 infection-mediated thrombosis, lending itself for testing therapeutics targeting selected targets with the advantage of capturing the cellular response on a rapid and small scale.
Abstract 16648: Covid-19 at the ICU: A Multiorgan Challenge
Authors: Andreas A Markl, Steffen Schnupp, Thomas Mischke, Georg Breuer, Johannes Brachmann, Christian Mahnkopf
Journal: Circulation (2020)

Introduction: About 5% of all COVID-19 patients require intensive care, mostly because of respiratory failure. Little is known about concomitant multi-organ manifestation under these circumstances. Methods: Retrospective observational study using routine data sets of 13 COVID-19 patients requiring mechanical ventilation in the Regiomed Hospital Coburg, Germany, between March 1 st and June 15 th , 2020. Results: Of 13 patients eligible for this study, all were intubated and ventilated mechanically, with signs of infiltration in chest radiographs. 4 suffered from renal failure and needed dialysis; 3 of these patients died, but none without renal failure. Proteinuria was found in all and microhematuria in all but one patients tested (n=11). All developed metabolic alkalosis (BEmax 9.75±0.99, mean ±SEM), and 6 afterwards polyuria (6.75 ±2.45l per day); both conditions resolved in all surviving patients but 1 spontaneously and were not related to prior renal failure. Liver enzymes were elevated in all patients (γGT 506 ±78U/l), but bilirubin levels only in 4; 2 of these died shortly after. Bacterial superinfection was found in 8 patients, and in all 3 ones finally dying. Rhabdomyolysis affected 12 patients (CKmax 1604±542U/l) and resolved later. All patients had slightly elevated troponin T (0.059 ±0.013ng/ml), and 7 had elevated nt-pro-BNP levels (3566±2359pg/ml), indicating cardiac COVID-19, and elevated d-dimer levels (18.1 ±6.68mg/dl) representing disseminated intravascular coagulation. No thromboembolic was observed. The need of catecholamines was low (&lt;1mg/h norepinephrine), as long as there was no septic complication. Conclusions: Our data indicate that severe COVID-19 is a multi-organ disease, even though ARDS is the leading problem; renal involvement - together with bacterial superinfection - seems to be a major risk factor for unfavorable disease development. Especially metabolic alkalosis and polyuria without overt renal failure have not been studied yet and require close clinical attention.
22P HER2-low vs HER2-zero metastatic breast carcinoma: A clinical and genomic descriptive analysis
Authors: R. Sanchez Bayona, A.M. Luna, P. Tolosa, A. Sánchez De Torre, A. Castelo, M. Marín, C. García, V. Boni, E. Bernal Hertfelder, E. Vega, B. Rojas, R. Bratos, M. Martínez, Á.J. Díaz Bermejo, L. Lema, L. Manso, E.M. Ciruelos
Journal: Annals of Oncology (2021)